Last reviewed · How we verify

interferon α 2b + ribavirin — Competitive Intelligence Brief

interferon α 2b + ribavirin (interferon α 2b + ribavirin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy. Area: Virology / Infectious Disease.

marketed Antiviral combination therapy Interferon-α receptor; viral RNA-dependent RNA polymerase Virology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

interferon α 2b + ribavirin (interferon α 2b + ribavirin) — The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz). Interferon α-2b activates innate immunity and has direct antiviral activity, while ribavirin inhibits viral RNA synthesis, together suppressing hepatitis C virus replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
interferon α 2b + ribavirin TARGET interferon α 2b + ribavirin The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) marketed Antiviral combination therapy Interferon-α receptor; viral RNA-dependent RNA polymerase
Ganovo+ritonavir+/-Interferon nebulization Ganovo+ritonavir+/-Interferon nebulization The Ninth Hospital of Nanchang marketed Antiviral combination therapy Viral RNA-dependent RNA polymerase; CYP3A4 (ritonavir); Interferon-alpha/beta receptors
Peginterferon alfa-2a, Ribavirin, epoetin-β Peginterferon alfa-2a, Ribavirin, epoetin-β Germans Trias i Pujol Hospital marketed Antiviral combination therapy with hematopoietic agent Interferon-α receptor; viral RNA polymerase; erythropoietin receptor
Quadruple therapy Quadruple therapy Sherief Abd-Elsalam marketed Antiviral combination therapy
Ribavirin, Peg interferon alfa 2b Ribavirin, Peg interferon alfa 2b Brooke Army Medical Center marketed Antiviral combination therapy HCV RNA-dependent RNA polymerase; interferon-alpha receptor
E: Peg-interferon alpha-2a & Ribavirin E: Peg-interferon alpha-2a & Ribavirin Kaohsiung Medical University Chung-Ho Memorial Hospital marketed Antiviral combination therapy Interferon-alpha receptor; viral RNA-dependent RNA polymerase
Xenical, Pegasys, Copegus Xenical, Pegasys, Copegus Brooke Army Medical Center marketed Antiviral combination therapy (interferon + nucleoside analog); Lipase inhibitor Hepatitis C virus NS5B polymerase; pancreatic lipase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy class)

  1. Kaohsiung Medical University Chung-Ho Memorial Hospital · 6 drugs in this class
  2. National Taiwan University Hospital · 6 drugs in this class
  3. Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
  4. Hepatitis Resource Network · 1 drug in this class
  5. Hospices Civils de Lyon · 1 drug in this class
  6. MTI Medical Private Limited, Pakistan · 1 drug in this class
  7. Pacific Health Foundation · 1 drug in this class
  8. RedHill Biopharma Limited · 1 drug in this class
  9. Sherief Abd-Elsalam · 1 drug in this class
  10. The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). interferon α 2b + ribavirin — Competitive Intelligence Brief. https://druglandscape.com/ci/interferon-2b-ribavirin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: